Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS EBITDA Margin

EBITDA as a percentage of revenue.

Oculis Holding AGNASDAQ: OCS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

What to watch

Whether next quarter's EBITDA Margin reaches the consensus estimate of -13403.5%, a -3785.4 pp change from the same quarter last year.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
-18676.3%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—-3785.4 pp—
1 year———
3 years———
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2024
-12468.1%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How OCS compares with its peers on the latest reported figures

  • OCS's LTM Mar 2026 EBITDA Margin of -18676.3% is the lowest of the 5 companies compared; the peer median is -1971.1%.
OCS Competitors Peer median
EBITDA Margin for OCS and competitors
Company Period LTM level YoY 3-year change
HROWHarrow Health, Inc.LTM Mar 202611.7% +3.4 pp+19.6 pp
OCULOcular Therapeutix, Inc.LTM Mar 2026-527.0% -231.3 pp-361.8 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-3415.1% -3156.5 pp-497.7 pp
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18634.1% -28166.9 pp—
OCSOculis Holding AGLTM Mar 2026-18676.3% ——
OKYOOKYO Pharma LimitedFY2025— ——
Peer median (excluding OCS) -1971.1%-1693.9 pp-361.8 pp

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000686K0
Cost of Revenue00052.08M0
Gross Profit000(51.4M)0
Gross Margin———-7492.3%—
Research & Development9.57M22.22M29.25M52.08M54.52M
Selling, General & Admin4.1M6.74M14.72M21.81M24.63M
Operating Expenses13.23M32.38M80.71M21.81M79.15M
Depreciation & Amortization235K299K287K406K521.45K
EBITDA(13.17M)(31.9M)(87.09M)(85.53M)(93.37M)
EBITDA Margin———-12468.1%—
Operating Income(13.23M)(32.38M)(80.71M)(73.2M)(79.15M)
Operating Margin———-10671.1%—
Interest Income21K126K1.59M2.17M1.69M
Interest Expense5.12M6.44M1.46M639K795.55K
Other Income / Expenses(5.29M)(6.27M)(7.98M)(12.73M)(15.54M)
Income Before Tax(18.52M)(38.64M)(88.7M)(85.94M)(94.69M)
Pre-Tax Margin———-12527.3%—
Income Tax Expense27K55K107K(160K)177.64K
Net Income(18.55M)(38.7M)(88.8M)(85.78M)(94.51M)
Net Margin———-12503.9%—
EPS (Basic)(0.57)(1.18)(2.97)(2.12)(1.81)
EPS (Diluted)(0.57)(1.18)(2.97)(2.12)(1.81)
Weighted Avg Shares32.73M32.73M29.9M40.41M52.36M
Weighted Avg Shares (Diluted)32.73M32.73M29.9M40.41M52.36M

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.